WALTHAM, MA / ACCESSWIRE / October 9, 2019 / EyeGate Pharmaceuticals, Inc. (EYEG) (“EyeGate” or “the Company”), a clinical-stage company focused on developing products for treating disorders of the eye, announced today that it has enrolled the...
The U.S. Food and Drug Administration today granted approval to Scenesse (afamelanotide) to increase pain-free light exposure in adult patients with a history of phototoxic reactions (damage to skin) from erythropoietic protoporphyria. For patients who are suffering...
SAN FRANCISCO, Oct. 7, 2019 /PRNewswire/ — Nektar Therapeutics (NASDAQ: NKTR) today announced the initiation of two Phase 1b studies of NKTR-358 (LY3471851*), a novel T regulatory (Treg) cell stimulator, one in patients with psoriasis and one in patients with...
YTX-7739 represents a novel, first-in-class, potentially disease-modifying therapy Data from Phase 1 study expected in the first quarter of 2020 CAMBRIDGE, Mass.–(BUSINESS WIRE)–Yumanity Therapeutics, a company focused on protecting the vitality of the...
NEW YORK, Oct. 8, 2019 /PRNewswire/ — Hoth Therapeutics, Inc. (Nasdaq: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and...
Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCell’s lead candidate, Bria-IMT™ in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced breast cancer. Cancer blocks the immune system preventing it...
Email
Text